



The Richard Doll Seminars
in Public Health and Epidemiology

Professor Karl Claxton

*Department of Economics
University of York*

“Which health technologies, at what price and for whom: estimating the cost-effectiveness threshold for NICE and the NHS”

Tuesday 26th May 2015
1-2 pm

Lecture Theatre, Richard Doll Bldg, Old Road Campus

<http://www.ceu.ox.ac.uk/seminars>

Follow us  [@rdseminars](https://twitter.com/rdseminars)

All welcome

Karl Claxton PhD

Professor of Economics
Department of Economics, and
Centre of Health Economics
University of York



Karl Claxton is a professor in the Department of Economics, and the Centre for Health Economics at the *University of York* and leads the economic evaluation component of the Health Economics MSc at the university. He is a past co-editor of the *Journal of Health Economics* and has held an adjunct appointment at the *Harvard School of Public Health*. He was a founding member of the *NICE Technology Appraisal Committee*. He has represented the committee at a number of appeals, and was an expert witness for the institute during judicial review. He is also a member of the *National Decision Support Unit* and continues to contribute to the development of the NICE Guide to the Methods of Technology Appraisal through the NICE Methodology Working Party.

He has contributed to recent policy debates such as pharmaceutical pricing and innovation, including as an expert witness at the House of Common Health Select Committee and the Kennedy review of Innovation in Health Technology. As well as NICE, he has also advised the Department of Health, HM Treasury, Department of Innovation and Skills and Office of Life Sciences. His expertise spans economic evaluation, Bayesian decision theory and health policy. He is author of two OUP textbooks on economic evaluation and decision modelling as well as many articles in leading international journals in health economics, decision science, statistics and health policy. The Financial Times has described him as probably the ‘*most dangerous economist to pharma companies and its investors*’ (19 Feb 2015).